483
Sarepta Therapeutics IncFDA 483 - Sarepta Therapeutics Inc - March 24, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Sarepta Therapeutics, Inc.'s biological drug testing lab in Andover, MA, revealed significant deficiencies in its quality control unit. The firm failed to timely investigate errors related to drug product stability, reference material, and release testing, leaving multiple quality events unresolved. Additionally, there was no written procedure for trending method failures, and a critical potency method exhibited a high failure rate.
Open in Dashboard
ID · bca73744-787b-49ec-99bb-17925f689f5a